Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matrices

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 799, Issue 1, 2004, Pages 15-22

  Soepenberg, Otto ^a   De Bruijn, Peter ^a   Verweij, Jaap ^a   Atsumi, Ryo ^b   Sparreboom, Alex ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b DAIICHI SANKYO CO   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Camptothecin; DE 310

Indexed keywords

ALCOHOLS; BLOOD; CELLS; ENZYMES; LIQUID CHROMATOGRAPHY; SEPARATION;

ERYTHROCYTES; HUMAN SALIVA;

BIOASSAY;

ALCOHOL DERIVATIVE; CAMPTOTHECIN DERIVATIVE; CARBOXYMETHYLDEXTRAN POLYOL CONJUGATE; DE 310; DNA TOPOISOMERASE INHIBITOR; EXATECAN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DETERMINATION; EFFLUENT; ELUTION; ENZYME INHIBITION; ERYTHROCYTE; HUMAN; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SALIVA; VALIDATION PROCESS;

EID: 0345059193     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2003.09.047     Document Type: Article

References (18)

1. Daiichi Pharmaceuticals UK Ltd., Investigator's Brochure, first ed., Daiichi Pharmaceuticals UK Ltd., London, 2000.
2. Maeda H., Matsumura Y. Crit. Rev. Ther. Drug Carrier Syst. 6:1989;193.
3. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. J. Control. Release. 65:2000;271.
4. Maeda H. Adv. Enzyme Regul. 41:2001;189.
5. Soepenberg O., de Jonge M., Sparreboom A., de Bruijn P., Eskens F., de Heus G., Langman S., Cheverton P., Bastien L., Verweij J. Proc. Am. Soc. Clin. Oncol. 22:2003;523. [Abstract].
6. Takimoto C.H., Forero L., Schwartz G.H., Tolcher A.W., Hammond L.A., Patnaik A., Ducharme M., Cooke B., De Jager R., Rowinsky E.K. Proc. Am. Soc. Clin. Oncol. 22:2003;522. [Abstract].
7. O. Soepenberg, A. Sparreboom, J. Verweij, in: G.A. Cordell (Ed.), The Alkaloids: Chemistry and Biology, vol. 60, Elsevier, Amsterdam, 2003, pp. 1-35.
8. Svensson C.K., Woodruff M.N., Baxter J.G., Lalka D. Clin. Pharmacokin. 11:1986;450.
9. Drobitch R.K., Svensson C.K. Clin. Pharmacokin. 23:1992;365.
10. Hinderling P.H. Pharmacol. Rev. 49:1997;279.
11. Loos W.J., van Zomeren D.M., Gelderblom H., Verweij J., Nooter K., Stoter G., Sparreboom A. J. Chromatogr. B. 766:2002;99.
12. Mi Z., Burke T.G. Biochemistry. 33:1994;10325.
13. Kehrer D.F.S., Soepenberg O., Loos W.J., Verweij J., Sparreboom A. Anticancer Drugs. 12:2001;89.
14. Oguma T., Ohshima Y., Nakaoka M. J. Chromatogr. B. 740:2000;237.
15. Oguma T., Yamada M., Konno T., Inukai K., Nakaoka M. Biol. Pharm. Bull. 24:2001;176.
16. Loos W.J., Stoter G., Verweij J., Schellens J.H.M. J. Chromatogr. B. 678:1996;309.
17. de Bruijn P., de Jonge M.J., Verweij J., Loos W.J., Nooter K., Stoter G., Sparreboom A. Anal. Biochem. 269:1999;174.
18. de Jong F.A., Mathijssen R.H.J., de Bruin P., Loos W.J., Verweij J., Sparreboom A. J. Chromatogr. B. 795:2003;383.